148516-11-4

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
Ethyl 2-cyclopropyl-4-(4-fluorophenyl)-quinolyl-3-carboxylate is used as a key component in the discovery and development of new pharmaceuticals due to its potential biological activities. It is particularly valuable for its possible applications in treating various conditions such as bacterial or viral infections, inflammation, or cancer.
Used in the Development of New Medicines:
In the pharmaceutical industry, Ethyl 2-cyclopropyl-4-(4-fluorophenyl)-quinolyl-3-carboxylate is utilized as a starting material or intermediate in the synthesis of innovative medicines. Its unique structure and properties make it a promising candidate for the creation of drugs that could address unmet medical needs.
The precise mechanism of action and the full spectrum of therapeutic uses for Ethyl 2-cyclopropyl-4-(4-fluorophenyl)-quinolyl-3-carboxylate would necessitate further research and clinical investigation to fully understand its potential and safety in medical applications.

InChI:InChI=1/C21H18FNO2/c1-2-25-21(24)19-18(13-9-11-15(22)12-10-13)16-5-3-4-6-17(16)23-20(19)14-7-8-14/h3-6,9-12,14H,2,7-8H2,1H3

Upstream product

• 3800-06-4 2-amino-4'-fluorobenzophenone 
• 24922-02-9 Ethyl 3-cyclopropyl-3-oxopropionate 
• 42840-02-8 2-(Toluene-4-sulfonylamino)-benzoyl chloride 
• 1765-93-1 4-fluoroboronic acid 
• 1885-29-6 anthranilic acid nitrile 
• 934560-46-0 N-[2-(4-fluorobenzoyl)phenyl]-4-methylbenzenesulfonamide 
• 118-92-3 anthranilic acid 
• 6311-23-5 2-(toluene-4-sulfonylamino)-benzoic acid 
• 765-43-5 Cyclopropyl methyl ketone 

Downstream Products

• 121660-37-5 2-cyclopropyl-4-(4-fluorophenyl)-3-formylquinoline 
• 148516-16-9 (1R,4S,6R)-4-{(E)-2-[2-Cyclopropyl-4-(4-fluoro-phenyl)-quinolin-3-yl]-vinyl}-3,7-dioxa-bicyclo[4.1.0]heptan-2-one 
• 148516-12-5 2-Cyclopropyl-4-(4-fluoro-phenyl)-3-phenylsulfanylmethyl-quinoline 
• 148516-15-8 (6S)-6-{(E)-2-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]vinyl}-5,6-dihydro-2H-pyran-2-one 
• 153968-97-9 2-cyclopropyl-4-(4-fluorophenyl)-3-iodoquinoline 
• 160375-37-1 2-Cyclopropyl-4-(4-fluoro-phenyl)-quinoline-3-carboxylic acid 
• 121660-11-5 2-cyclopropyl-4-(4-fluorophenyl)-3-(hydroxymethyl)quinoline 

Relevant academic research and scientific papers

Preparation method of intermediate of pitavastatin calcium

The invention relates to a preparation method of an intermediate 2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinecarboxylate of pitavastatin calcium. The method comprises the following steps: with 2-aminobenzonitrile and 3-cyclopropyl-3-oxo-propionate as star

Rapid and efficient synthesis of poly-substituted quinolines assisted by p-toluene sulphonic acid under solvent-free conditions: Comparative study of microwave irradiation versus conventional heating

A rapid and efficient method for the preparation of various poly-substituted quinolines has been developed through the Friedlaender condensation of 2-aminoarylketone or 2-aminoarylaldehyde with carbonyl compounds in the presence of p-toluene sulphonic aci

Synthesis and biological evaluations of quinoline-based HMG-CoA reductase inhibitors

A series of quinoline-based 3,5-dihydroxyheptenoic acid derivatives were synthesized from quinolinecarboxylic acid esters by homologation, aldol condensation with ethyl acetoacetate dianion, and reduction of 3-hydroxyketone to evaluate their ability to inhibit the enzyme HMG-CoA reductase in vitro. In agreement with previous literature, a strict structural requirement exists on the external ring, and 4-fluorophenyl is the most active in this system. For the central ring, substitution on positions 6, 7, and 8 of the central quinoline nucleus moderately affected the potency, whereas the alkyl side chain on the 2-position had a more pronounced influence on activity. Among the derivatives, NK-104 (pitavastatin calcium), which has a cyclopropyl group as the alkyl side chain, showed the greatest potency. We found that further modulation and improvement in potency at inhibiting HMG-CoA reductase was obtained by having the optimal substituents flanking the desmethylmevalonic acid portion, that is, 4-fluorophenyl and cyclopropyl, instead of the usual isopropyl group.

Practical synthesis of quinoline nucleus of NK-104

The development of practical synthetic procedure for a staple intermediate of NK-104, a highly advanced HMG-Co.A reductase inhibitor is reported.

A NOVEL SYNTHETIC METHOD OF HMG-CoA REDUCTASE INHIBITOR NK-104 VIA HYDROBORATION-CROSS COUPLING SEQUENCE

The regioselective hydroboration of ethyl (3R,5S)-3,5-isopropylidenedioxy-6-heptynoate, followed by the cross-coupling reaction with an aryl halide, provides ethyl (3R,5S,6E)-7-aryl-3,5-isopropylidenedioxy-6-heptenoate, a precursor of a highly potent HMG-